Tag: Cabaletta Bio's
Cabaletta Bio’s IND application for CABA-201 to treat systemic lupus erythematosus has been approved by the US FDA.
The US Food and Drug Administration has approved the company’s investigational new drug (IND) application for CABA-201, a…
Registration Form
This will close in 0 seconds
